Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.

Trial Details

NCT ID
NCT06279351
Phase
PHASE2
Sponsor
Xinqiao Hospital of Chongqing
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Thalidomide+cetuximab+FOLFOX/FOLFIRI
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
  • Physical state is good: PS 0-2;
  • Expected survival of more than 3 months;
  • Aged 18-75 years old;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →